Sebastian A. Brunemeier

Partner & Co-Founder @ LongGame Ventures

About

Building and investing in longevity biotech ("LongBio") companies that address the molecular mechanisms of aging ("geroscience"). - Partner & Cofounder @ Long Game Ventures, Healthspan Capital - Co-founder & CIO of Cambrian Bio - Principal at Apollo Health Ventures - Founder & COO of Samsara Therapeutics - CEO @ ImmuneAGE Bio, Cyclone Tx - Oxford Biochemistry PhD (DPhil) dropout (to co-found Cambrian) and Clarendon Scholar - MSc in Molecular Neuro & Biotech Business Management @ Uni Amsterdam - Advisor to Longevity Biotech Fellowship, VitaDAO + Bio: Sebastian Aguiar Brunemeier is a biotech VC and company builder focused on longevity & regenerative medicine. He is Co-Founder and General Partner of Healthspan Capital, and CEO and Founder of ImmuneAGE Bio (stealth), focused on immune system rejuvenation. Over the last 5 years, he has co-founded 4 longevity biotech (“LongBio”) companies with a total equity value of >$600M. He was Co-Founder and Chief Investment Officer at Cambrian Biopharma, Founder and COO of Samsara Therapeutics, and Principal at Apollo Health Ventures (the first and largest aging-focused venture capital fund in the world with $200M AUM). Altogether, these organizations have raised ±$400M in the last 4 years. He was a Fulbright Fellow on the biology of aging, a Skaggs-Oxford Scholar at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. His education includes dropping out of the DPhil (PhD) program in biochemistry of aging at the University of Oxford as a Clarendon Scholar (to launch a biotech startup called Cambrian), a Master’s in Life Science Business Management and Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. He served as trustee of the British Society for Research on Aging, a mentor at The New York Academy of Sciences, and as an advisor or board member to: VitaDAO/Molecule.to, Equator Therapeutics, and Revivo Therapeutics. A few of my presentations: https://www.youtube.com/playlist?list=PL1fK3UMPdqMvp_YbqK2fnPkTQBOYD2ww4

Country

Portugal

City

Lisbon

Industry

Venture Capital & Private Equity

Skill

Venture Capital, Drug Discovery, Biotechnology, Molecular Biology, Project Management, Biochemistry, Microsoft Excel, Public Speaking, Money Laundering, Creative Accounting, Extortion, Debate, Supercritical Fluids, GraphPad Prism

Experience

Partner & Co-Founder

LongGame Ventures

2024-11 - Present · 1 yr 11 mos

London

Funding longevity biotech (LongBio) & frontier bio.

Co-founder & Partner

Healthspan Capital

2021-8 - Present · 5 yrs 2 mos

San Francisco

Venture fund focused on longevity biotech ("LongBio") & geroscience. healthspancapital.vc

Advisor

Longevity Biotech Fellowship

2022-11 - Present · 3 yrs 11 mos

San Francisco, California, United States

Faculty Lecturer

Geneva College of Longevity Science

2024-5 - Present · 2 yrs 5 mos

Geneva, Switzerland

Founder

LongBio Institute

2024-8 - Present · 2 yrs 2 mos

United States

Advancing the field of Longevity Biotech (LongBio). Launching soon!

Longevity Working Group

VitaDAO

2020-9 - Present · 6 yrs 1 mo

Switzerland

Financing longevity biotech ("LongBio") and academic partnerships via a decentralized autonomous organization. https://www.vitadao.com/

Initiator & Committee Member

Longevity Prize

2022-6 - Present · 4 yrs 4 mos

Global

Prizes for novel ideas in the geroscience & LongBio fields. Supported by Foresight Institute, VitaDAO, LEAF, etc. https://www.longevityprize.com/

Advisory Board

Alpine Institute

2022-1 - Present · 4 yrs 9 mos

Zurich, Switzerland

Swiss longevity clinic

Advisor

Molecule

2020-9 - Present · 6 yrs 1 mo

Switzerland

A decentralized stock exchange and licensing platform for biotech intellectual property. Originators of the VitaDAO decentralized financing platform for longevity biotech.

Board Member

Revivo Therapeutics

2020-11 - Present · 5 yrs 11 mos

Chapel Hill, North Carolina, United States

Revivo Therapeutics is clinical-stage pharmaceutical company developing a new class of cognitive-enhancing small molecules: nomethiazoles, which act as nitric oxide donor prodrugs and GABA(A) positive allosteric modulators. This results in CREB activation, vasodilation, reduced neuroinflammation, and reduced excitotoxicity. This MoA is neuroprotective in many animal models of CNS disease and cognitive decline. Revivo has been funded by the NIH, ADDF, and private venture capital, and we are raising capital for our clinical trials now

Education

University of Oxford

Biochemistry of aging. Clarendon Scholarship

Clarendon Scholar (awarded to the top ±1% of graduate students: https://en.wikipedia.org/wiki/Clarendon_Fund ) Attended Lincoln College (the college of Howard Florey, Nobel Laureate for penicillin drug development). Doctoral (DPhil/PhD) thesis research on the biochemistry of ageing -- focused on drug discovery at the interface of cellular senescence, proteostasis, and autophagy. Paused to co-found a biotech company. https://www.timeshighereducation.com/world-university-rankings/2022/world-ranking#!/page/0/length/25/sort_by/rank/sort_order/asc/cols/stats

Scripps Research

Dept of Molecular Medicine

Scripps is the largest private biomedical research institute in the US with a budget >$300M/yr and ±10 approved drugs. Outperforming all other research institutions on a per capita / per publication basis: https://www.natureindex.com/supplements/nature-index-2017-innovation/tables/top100-institutions-lens

University of Amsterdam

Biomedical Science (Molecular Neuroscience)

UvA is the #1 ranked and largest university in the Netherlands. Coursework: - Neurodevelopment and Specification of Neural Systems - Stem Cell Fate and Cortical Genesis - Neuronal Signal Transduction Pathways - Research thesis on BCL2 signaling and neurodegeneration (Lars van der Heide and Marten Smidt labs)

Vrije Universiteit Amsterdam (VU Amsterdam)

Life Science Business Management

Thesis: "Evaluating Preclinical Drug Discovery Programs for Venture Capital: A Quantitative Model" Coursework: - Finance for Life Sciences (venture capital, equity research, rNPV & real options modeling) - Business Development and Technology Licensing (Prof Eric Claassen) - Business Management in Health and Life Sciences - Research Methods for Complex Problems - Analysis of Government Policy - Communication, Organization, and Management - Full course title: "Management, Policy-Analysis & Entrepreneurship in Health and Life Sciences"

Pitzer College

Human Biology (Honors)

Pitzer is one of the Claremont Colleges in Southern California. The consortium includes Pomona, Scripps, Claremont McKenna, and Harvey Mudd. There are also three Claremont grad schools: the Keck Graduate Institute (biotech), Claremont Graduate Institute, and the Drucker School of Management. I majored in Human Biology, and focused my coursework on neuroscience and molecular biology. Some of my extracurriculars are listed above. I minored in history, focusing on early 20th century financial crises and political economy. Topics of interest included: Standard Oil, J.P. Morgan, the Labor Movement, the Federal Reserve System, Black Tuesday 1929, The Great Depression and New Deal, etc. I also read Fernand Braudel on the emergence of capitalism and banking in the Early Modern Period. My view toward economics is historical. Basing the entire theoretical foundation of finance and portfolio theory on a mere 60-year post-war period dataset is absurd.